Drug Trial Radar · NCT03989947
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
Last checked: Nov 20, 2026Latest source record: Mar 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
73
Actual
Start
Jun 12, 2019
Primary completion
May 2038
Study completion May 2038
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- Jun 18, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 15 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, open-label multi-center long-term extension study, with approximately 70 subjects, to evaluate the safety and efficacy of BMN111 in children with Achondroplasia until subjects reach near-adult final height. Eligible subjects will have completed 1 year of BMN111 or placebo treatment in the 111-206 study and once enrolled in the 111-208 extension study will receive a daily dose of BMN111 by subcutaneous injection according to their age as determined by 111-206.
Conditions
- Achondroplasia
Interventions
Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.Drug
Modified recombinant human C-type natriuretic peptide (subject to adjustment per protocol)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: "Through study completion, an average of 5 years"
- Evaluate change in height/length z-score in children with ACH treated with BMN 111Time frame: "Through study completion, an average of 5 years"
Locations
16 sites in 4 countries. Site status is shown where the registry gives one.
Children's Hospital & Research Center Oakland
Oakland, California
Harbor - UCLA Medical Center
Torrance, California
Alfred I. duPont Hospital for Children
Wilmington, Delaware
Emory University
Decatur, Georgia
Ann Robert and H. Lurie Children's Hospital of Chicago
Chicago, Illinois
Cincinnati Childrens Hospital
Cincinnati, Ohio
Vanderbilt University Medical Center
Nashville, Tennessee
Baylor College of Medicine
Houston, Texas
Medical College of Wisconsin, Children's Hospital
Milwaukee, Wisconsin
The Children's Hospital at Westmead
Westmead, New South Wales, Australia
Murdoch Children's Research Institute
Parkville, Victoria, Australia
Osaka University
Osaka, Japan
Saitama Children's Medical Center
Saitama, Japan
Tokushima University Hospital
Tokushima, Japan
Guy's and St. Thomas NHS Foundation Trust Evelina Children's Hospital
London, United Kingdom
Sheffield Children's NHS Foundation Trust
Sheffield, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.